This is the authors' abstract. We don't add key points for this paper.
The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection. (ClinicalTrials.gov number, NCT00350298.)
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lowy et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: